Received Apr 30, 2025
| Type | Name | Manufacturer | Dose | Lot | Route / Site |
|---|---|---|---|---|---|
| DTAPIPV | DTAP + IPV (KINRIX) | GLAXOSMITHKLINE BIOLOGICALS | UNK | 34mf9 | — |
10 year-old female patient that on 4/17/2025 received Kinrix; This non-serious case was reported by a other health professional via call center representative and described the occurrence of inappropriate age at vaccine administration in a 10-year-old female patient who received DTPa-IPV (Kinrix) (batch number 34mf9, expiry date 13-FEB-2026) for prophylaxis. Concomitant products included Proquad and Hepatitis b vaccine rHBsAg (yeast) (Engerix b). On 17-APR-2025, the patient received Kinrix. On 17-APR-2025, an unknown time after receiving Kinrix, the patient experienced inappropriate age at vaccine administration (Verbatim: 10 year-old female patient that on 4/17/2025 received Kinrix). The outcome of the inappropriate age at vaccine administration was not applicable. This report is made by GSK without prejudice and does not imply any admission or liability for the incident or its consequences. Additional Information: GSK Receipt Date: 25-APR-2025 Medical Assistant had a 10 year-old patient that received Kinrix , which led to inappropriate age at vaccine administration. The patient also received Proquad and Engerix-B. There was no vaccination records. The Vaccine Administration Facility was the same as Primary Reporter. The reporter did not consent to follow-up.
PROQUAD; ENGERIX B